Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reaffirmed at Cowen and Company
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reiterated by Cowen and Company in a research report issued to clients and investors on Saturday. They currently have a $100.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $150.00. Cowen and Company’s price target would suggest a potential upside of 191.80% from the stock’s previous close.
A number of other research firms also recently issued reports on ALNY. JPMorgan Chase & Co. downgraded shares of Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $83.00 to $51.00 in a research note on Thursday. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 25th. FBR & Co reissued an “outperform” rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 27th. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $77.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Jefferies Group decreased their target price on shares of Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating for the company in a research note on Thursday. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. The stock has a 50 day moving average price of $70.69 and a 200 day moving average price of $66.05. Alnylam Pharmaceuticals has a 52-week low of $33.16 and a 52-week high of $110.75. The company’s market capitalization is $2.94 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/alnylam-pharmaceuticals-alny-outperform-rating-reaffirmed-at-cowen-and-company.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same period in the prior year, the firm earned ($0.85) earnings per share. Alnylam Pharmaceuticals’s revenue was up .2% on a year-over-year basis. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.00% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of ALNY. Aperio Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 8,328 shares in the last quarter. Pacad Investment Ltd. bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at about $490,000. BlackRock Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 15,965 shares in the last quarter. BlackRock Group LTD boosted its stake in shares of Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock valued at $32,630,000 after buying an additional 93,450 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock valued at $115,395,000 after buying an additional 112,252 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.